CYP1A1

Overview

CYP1A1 (cytochrome P450 family 1 subfamily A member 1) encodes a phase I metabolic enzyme involved in the oxidative metabolism of polycyclic aromatic hydrocarbons and other xenobiotics. It is a direct transcriptional target of the aryl hydrocarbon receptor (AHR). In cancer pharmacogenomics, CYP1A1 expression is regulated downstream of AHR and is suppressed by MEK inhibitor treatment in NRAS-mutant melanoma cell lines, implicating the AHR-CYP1A1 axis in MEK inhibitor response.

Alterations observed in the corpus

• CYP1A1 expression reduced by MEK inhibitors (PD-0325901) in NRAS-mutant melanoma cells; acts downstream of AHR as a transcriptional target PMID:22460905

Cancer types (linked)

• Melanoma (NRAS-mutant): CYP1A1 expression is suppressed by MEK inhibition; regulation is downstream of AHR PMID:22460905

Co-occurrence and mutual exclusivity

• CYP1A1 expression is co-regulated with AHR in NRAS-mutant melanoma cell lines; both are suppressed by MEK inhibitor treatment PMID:22460905

Therapeutic relevance

• CYP1A1 suppression is a pharmacodynamic marker of MEK inhibitor activity in NRAS-mutant melanoma; profiled in the Cancer Cell Line Encyclopedia (CCLE) across 947 cancer cell lines PMID:22460905

Open questions

• Whether CYP1A1 expression changes upon MEK inhibition represent a driver of response or a bystander effect of AHR pathway suppression remains unclear PMID:22460905

Sources

• PMID:22460905 — Cancer Cell Line Encyclopedia (CCLE) pharmacogenomic profiling of 947 cancer cell lines

This page was processed by entity-page-writer on 2026-05-06.